The Conflict between Emerging SARS-Cov-2 Variants and the Potential Immune Response with Vaccination

A. F.
{"title":"The Conflict between Emerging SARS-Cov-2 Variants and the Potential Immune Response with Vaccination","authors":"A. F.","doi":"10.23880/aii-16000148","DOIUrl":null,"url":null,"abstract":"The emergence of variants of the SARS-CoV-2 virus is certainly a serious threat to controlling the COVID-19 pandemic. After its irruption, some variants disappear or are irrelevant and others persist and are concerning because of its potential health repercussions and the immune response of vaccines that are being administered with great effort. One of the reasons why the SARS-CoV-2 virus is generating variants and will continue to do so is because a relatively few people in the world are immune and protected. The virus replicating is communicating to us that it is going to exhibit a lot of changes. Acquiring the infection involves risks of serious illness and death, so immunization is more logical, convincing and indispensable. It is also a better recourse for slowing viral replication, since infection offers viruses the opportunity to improve their performance. In addition, since multiple treatments, including antibody-based treatments, are often administered in severe infections, the surviving escape variants may be more resistant to these therapies effective against earlier versions of the virus. Two contenders (the surviving virus and the immune system) will be confronted with each other in an attempt to win, with the virus utilizing new weapons and subterfuges in a race that will lead to an evolutionary deadlock. A rising concern is whether available vaccines and those under investigation have a reduced or inadequate level of protection against emerging variants of SARS-CoV-2, particularly the variants of concern with changes in the spike protein. Despite these ongoing threats, at this time the general preventive measures and protection offered by the available SARS-CoV-2 vaccines are already a fundamental resource in the fight against COVID-19 and its variants, and a very hopeful measure for the immediate future. In the current situation, people should be aware of and learn to live with the virus variants and how to optimize its prevention and control.","PeriodicalId":409855,"journal":{"name":"Annals of Immunology & Immunotherapy","volume":"5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Immunology & Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23880/aii-16000148","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The emergence of variants of the SARS-CoV-2 virus is certainly a serious threat to controlling the COVID-19 pandemic. After its irruption, some variants disappear or are irrelevant and others persist and are concerning because of its potential health repercussions and the immune response of vaccines that are being administered with great effort. One of the reasons why the SARS-CoV-2 virus is generating variants and will continue to do so is because a relatively few people in the world are immune and protected. The virus replicating is communicating to us that it is going to exhibit a lot of changes. Acquiring the infection involves risks of serious illness and death, so immunization is more logical, convincing and indispensable. It is also a better recourse for slowing viral replication, since infection offers viruses the opportunity to improve their performance. In addition, since multiple treatments, including antibody-based treatments, are often administered in severe infections, the surviving escape variants may be more resistant to these therapies effective against earlier versions of the virus. Two contenders (the surviving virus and the immune system) will be confronted with each other in an attempt to win, with the virus utilizing new weapons and subterfuges in a race that will lead to an evolutionary deadlock. A rising concern is whether available vaccines and those under investigation have a reduced or inadequate level of protection against emerging variants of SARS-CoV-2, particularly the variants of concern with changes in the spike protein. Despite these ongoing threats, at this time the general preventive measures and protection offered by the available SARS-CoV-2 vaccines are already a fundamental resource in the fight against COVID-19 and its variants, and a very hopeful measure for the immediate future. In the current situation, people should be aware of and learn to live with the virus variants and how to optimize its prevention and control.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新出现的SARS-Cov-2变体与接种疫苗可能产生的免疫反应之间的冲突
SARS-CoV-2病毒变种的出现无疑是对控制COVID-19大流行的严重威胁。病毒侵入后,一些变异消失或无关紧要,而另一些则持续存在,令人担忧,因为其潜在的健康影响和正在努力接种的疫苗的免疫反应。SARS-CoV-2病毒正在产生变体并将继续这样做的原因之一是因为世界上相对较少的人是免疫和受保护的。病毒复制是在告诉我们,它将会出现很多变化。获得感染涉及严重疾病和死亡的风险,因此免疫接种更具逻辑性、说服力和不可或缺性。这也是减缓病毒复制的更好途径,因为感染为病毒提供了改善其性能的机会。此外,由于严重感染通常采用多种治疗方法,包括基于抗体的治疗方法,因此幸存的逃逸变体可能对这些对早期病毒有效的治疗方法更具抵抗力。两个竞争者(幸存的病毒和免疫系统)将为了获胜而相互对抗,病毒将利用新的武器和诡计在一场将导致进化僵局的竞赛中获胜。一个日益引起关注的问题是,现有疫苗和正在研究的疫苗对新出现的SARS-CoV-2变种,特别是与刺突蛋白变化有关的变种,是否具有较低或不足的保护水平。尽管存在这些持续的威胁,但目前,可用的SARS-CoV-2疫苗提供的一般预防措施和保护已经成为抗击COVID-19及其变体的基本资源,并且在不久的将来是一项非常有希望的措施。在当前形势下,人们应该意识到并学会与病毒变体共存,以及如何优化其防控。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
COVID-19 and Long Covid as Complex, Multi-Organs Involvement and Multi-System Disease Immunological Disorders in Adult Patients with Trichophytia and Microsporia of the Genital Area, Tajikistan How is the Mechanism of Immunodeficiency Caused by Metallic Implants and What Can they Cause when Inside the Patient's Body? Co-occurrence of Rheumatoid Arthritis and Pulmonary Tuberculosis: A Diagnostic and Therapeutic Challenge The Passing Pandemic? Perspective and Projections for COVID-19
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1